Molekulardiagnostik des nichtkleinzelligen Lungenkarzinoms: Neue Marker und Technologien

A. Warth; V. Endris; M. Kriegsmann; A. Stenzinger; R. Penzel; N. Pfarr; W. Weichert

doi:10.1007/s00292-015-0004-4

Molekulardiagnostik des nichtkleinzelligen Lungenkarzinoms: Neue Marker und Technologien

Translated title of the contribution: Molecular diagnostics of non-small cell lung cancer: New markers and technologies

A. Warth
, V. Endris
, M. Kriegsmann
, A. Stenzinger
, R. Penzel
, N. Pfarr
, W. Weichert

University Hospital Heidelberg
Translationales Lungenforschungszentrum Heidelberg (TLRCH)
Nationales Centrum für Tumorerkrankungen (NCT) Heidelberg

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

Abstract

Lung cancer is the prototypical tumor entity for the development of new diagnostic and individualized therapeutic strategies based on molecular patient stratification. Developments in this field specifically concentrate on predictive biomarkers for the response to conventional therapeutic agents, novel drugs targeting specific mutations and also new immunomodulatory drugs. The multitude of upcoming new predictive biomarkers requires the development and implementation of efficient test strategies and comprehensive technical methods, specifically when tissue restrictions inherent to lung cancer diagnostics are also taken into account. Novel procedures and technical aspects of these issues are discussed in this review.

Translated title of the contribution	Molecular diagnostics of non-small cell lung cancer: New markers and technologies
Original language	German
Pages (from-to)	154-163
Number of pages	10
Journal	Pathologe
Volume	36
Issue number	2
DOIs	https://doi.org/10.1007/s00292-015-0004-4
State	Published - 1 Mar 2015
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1007/s00292-015-0004-4

Cite this

@article{7ced7c671c0d46958ec1619585ccc888,

title = "Molekulardiagnostik des nichtkleinzelligen Lungenkarzinoms: Neue Marker und Technologien",

abstract = "Lung cancer is the prototypical tumor entity for the development of new diagnostic and individualized therapeutic strategies based on molecular patient stratification. Developments in this field specifically concentrate on predictive biomarkers for the response to conventional therapeutic agents, novel drugs targeting specific mutations and also new immunomodulatory drugs. The multitude of upcoming new predictive biomarkers requires the development and implementation of efficient test strategies and comprehensive technical methods, specifically when tissue restrictions inherent to lung cancer diagnostics are also taken into account. Novel procedures and technical aspects of these issues are discussed in this review.",

keywords = "Immunomodulatory drugs, Lung cancer, Massively parallel sequencing, Molecular diagnostics, Sequential testing",

author = "A. Warth and V. Endris and M. Kriegsmann and A. Stenzinger and R. Penzel and N. Pfarr and W. Weichert",

note = "Publisher Copyright: {\textcopyright} 2015, Springer-Verlag Berlin Heidelberg.",

year = "2015",

month = mar,

day = "1",

doi = "10.1007/s00292-015-0004-4",

language = "Deutsch",

volume = "36",

pages = "154--163",

journal = "Pathologe",

issn = "0172-8113",

publisher = "Springer Medizin",

number = "2",

}

TY - JOUR

T1 - Molekulardiagnostik des nichtkleinzelligen Lungenkarzinoms

T2 - Neue Marker und Technologien

AU - Warth, A.

AU - Endris, V.

AU - Kriegsmann, M.

AU - Stenzinger, A.

AU - Penzel, R.

AU - Pfarr, N.

AU - Weichert, W.

PY - 2015/3/1

Y1 - 2015/3/1

N2 - Lung cancer is the prototypical tumor entity for the development of new diagnostic and individualized therapeutic strategies based on molecular patient stratification. Developments in this field specifically concentrate on predictive biomarkers for the response to conventional therapeutic agents, novel drugs targeting specific mutations and also new immunomodulatory drugs. The multitude of upcoming new predictive biomarkers requires the development and implementation of efficient test strategies and comprehensive technical methods, specifically when tissue restrictions inherent to lung cancer diagnostics are also taken into account. Novel procedures and technical aspects of these issues are discussed in this review.

AB - Lung cancer is the prototypical tumor entity for the development of new diagnostic and individualized therapeutic strategies based on molecular patient stratification. Developments in this field specifically concentrate on predictive biomarkers for the response to conventional therapeutic agents, novel drugs targeting specific mutations and also new immunomodulatory drugs. The multitude of upcoming new predictive biomarkers requires the development and implementation of efficient test strategies and comprehensive technical methods, specifically when tissue restrictions inherent to lung cancer diagnostics are also taken into account. Novel procedures and technical aspects of these issues are discussed in this review.

KW - Immunomodulatory drugs

KW - Lung cancer

KW - Massively parallel sequencing

KW - Molecular diagnostics

KW - Sequential testing

UR - https://www.scopus.com/pages/publications/84937759622

U2 - 10.1007/s00292-015-0004-4

DO - 10.1007/s00292-015-0004-4

M3 - Artikel

C2 - 25820445

AN - SCOPUS:84937759622

SN - 0172-8113

VL - 36

SP - 154

EP - 163

JO - Pathologe

JF - Pathologe

IS - 2

ER -

Molekulardiagnostik des nichtkleinzelligen Lungenkarzinoms: Neue Marker und Technologien

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this